RARECast

RARECast

By RARECastBusiness
Download on the App Store

RARECast episodes

  • Albireo Advances Pipeline for Rare Liver and Gastrointestinal Diseases
    PFIC is a rare genetic disorder that causes progressive, life-threatening liver disease. In many cases, PFIC leads to cirrhosis and liver failure within the first 10 years of life. Albireo, a 2008 spin-out of AstraZeneca, is developing bile acid modulators to treat PFIC and other rare pediatric liver diseases and gastrointestinal disorders. We spoke to Ron Cooper, CEO of Albireo, about PFIC, the challenge of developing a therapy for a disease with multiple forms and causes, and the path forward for the company.
    20 min
  • aTyr Pharma Seeks to Modulate Activity in FSHD and Other Rare Disease
    aTyr Pharma is exploring a new set of naturally occurring proteins within the body dubbed physiocrines that modulate biologic activity and may provide therapeutic benefit. The company is pursuing this new class of molecules to treat a number of rare diseases. The company’s lead drug candidate Resolaris is being developed to treat FSHD, a rare genetic myopathy in which immune cells invade diseased skeletal muscle and cause muscles to grow weak and deteriorate. We spoke to John Mendlein, CEO of Atyr Pharma, about physicorines, how they can restore homeostasis to the immune and other systems, and why these molecules might be harnessed to treat a range of diseases.
    18 min
  • Summit Pursues A Different Approach to Treating Duchenne
    Duchenne Muscular Dystrophy, a rare genetic disease, causes progressive muscle wasting that slowly robs people of abilities and leads to death. In recent years, much attention has focused on the use of antisense oligonucleotides to bypass defective portions of the exon that codes for the dystrophin gene to restore its production. Dystrophin is a protein that is essential to healthy muscle. Summit Therapeutics is taking a different approach. Instead of restoring dystrophin, Summit is developing a drug that activate utrophin, a related protein that serves a similar function to dystrophin during fetal development, but then shuts off. We spoke to Glyn Edwards, CEO of Summit, about the company’s utrophin activator ezutromid, its licensing deal with Sarepta Therapeutics, and why, unlike the exon-skipping drugs that target specific subpopulaitons of Duchenne patients, ezutromid could provide benefits to patients broadly.
    39 min
  • Delivering Enzyme Replacement Therapies Across the Blood-Brain Barrier
    Enzyme replacement therapies are available for a number rare, metabolic diseases that collectively are known as lysosomal storage disorders. These therapies have brought great benefits to patients. One problem, though, is that the enzymes don’t cross the blood-brain barrier and don’t address the severe and progressive neurological complications caused by many of these diseases. ArmaGen thinks it has a solution. By connecting the enzyme to a protein that is allowed to cross the blood-brain barrier, ArmaGen hopes to exploit a natural mechanism to address the CNS complications of these diseases. We spoke to Mathias Schmidt, CEO of ArmaGen, about the company’s platform technology, its pipeline of enzyme replacement therapies for lysosomal storage disorders, and its implications for more common neurological diseases.
    31 min
  • Sangamo Advances Gene Editing Therapies for Multiple Rare Diseases into the Clinic
    The promise of gene editing and gene therapy has rare disease patients not only contemplating the potential of new treatments, but ones that can free them from chronic therapies and potentially provide cures. Sangamo Therapeutics, long pursuing its proprietary gene editing technology, is suddenly moving into the clinic with four experimental therapies including a a gene therapy for hemophilia A, and gene editing therapies for hemophilia B, MPS I, and MPS II. The company is currently enrolling three trials and expects to begin enrollment on a fourth trial later this month. We spoke to Sandy Macrae, president and CEO of Sangamo, about the diseases it is targeting, the company’s unique approach to gene editing, and it strategy for moving its therapies through clinical development and to the market.
    32 min
  • Navigating the Challenges of Rare Disease Drug Development
    Clinical trials for rare disease therapies face many challenges due to the small patient population on which they draw, the fact that often there may be many unanswered questions about a specific disease, and the potential variation in the way a rare disease manifests itself in patients. We spoke to John Boland, vice president of product development for the Atlantic Research Group, about the contract research organization’s recent white paper on “Critical Considerations for Rare and Orphan Disease Trial Planning” (http://bit.ly/2qE2qpb), the special challenges of conducting rare disease clinical trials, and how to best address these unique challenges.
    23 min
  • Accelerating Rare Disease Drug Discovery
    For many rare disease patients, the drug discovery and development process moves slower than the diseases they are battling. Earlier this month, representatives of the patient community joined with academic researchers and drug developers at the Charles River Rare Disease Symposium in Cambridge, Massachusetts to explore way to accelerate the process of drug discovery and move more quickly toward human clinical trials. We spoke to Doug Macdonald, director of research operations and scientific alliances for CHDI Management and Antti Nurmi, managing director of Charles River Discovery Services, about the obstacles to rare disease drug discovery, the critical role collaborations play, and what can be done to accelerate the process.
    23 min
  • Experimental Rare Disease Therapy Wins New FDA Reg Med Designation
    Last month the U.S. Food and Drug Administration granted Enzyvant both Breakthrough Therapy Designation and the newly established Regenerative Medicine Advanced Therapy Designation for its investigational cell therapy to treat complete DiGeorge Syndrome, a rare and fatal disease. Enzyvant is the first company to win both designations and only the second to win the Regenerative Medicine Advanced Therapy Designation established through the 21st Century Cures Act. The designations provide for accelerated review pathways and special access to developmental guidance from the FDA. We spoke to Alvin Shih, CEO of Enzyvant and Louise Markert, the Duke University immunologist who has been pioneering the therapy, about Complete DiGeorge Syndrome, the innovative approach they are using to treat it, and the path forward for the therapy. As a matter of disclosure, Shih is co-chair of Global Genes Medical and Scientific Advisory Board.
    18 min
  • How Rare Disease Patients Can Get their Voices Heard in Drug Discovery and Development
    There is increasing recognition of the important role patients can play by providing their insights into the drug discovery and development process. The Penn Medicine Orphan Disease Center and Global Genes will be hosting the second annual Rare Patient Advocacy Symposium in Philadelphia May 19, at the Sheraton University City Hotel, a day-long exploration of how rare disease patients can better get their voices heard in this process. We spoke to David Fajgenbaum, associate director of patient impact for the Penn Medicine Orphan Disease Center and research assistant professor of Medicine at the Perelman School of Medicine, about the changing view of rare disease patients, their emerging role in the drug development process, and the value they can provide to researchers, regulators, and drug developers.
    17 min
  • One Patient's Difficult Road to a Rare Diagnosis
    Porphyria is a rare and intensely painful blood disease. Because it can manifest itself with symptoms similar to those caused by far more common disorders, it can be difficult to diagnose. Colin McEwen went through an 18-year diagnostic odyssey, in part because injuries he suffered as a child from an auto accident obscured from doctors the actual cause of his maladies. His problems were made that much more difficult as his search for relief from the pain from his disease led doctors to dismiss him as a drug-seeker. We spoke to McEwen about porphyria, the experiences he went through to get to a diagnosis, and how having a diagnosis has changed his ability to manage the disease.
    21 min

About RARECast

From the publisher's feed

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.